Carregant...
Factors associated with potentially inappropriate phosphodiesterase-5 inhibitor use for pulmonary hypertension in the US, 2006–2015
BACKGROUND: Use of phosphodiesterase-5 inhibitors for Groups 2 and 3 pulmonary hypertension is rising nationally, despite guidelines recommending against this low-value practice. Although receiving care across healthcare systems is encouraged to increase Veterans’ access to specialists critical for...
Guardat en:
| Publicat a: | Circ Cardiovasc Qual Outcomes |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7344878/ https://ncbi.nlm.nih.gov/pubmed/32393128 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCOUTCOMES.119.005993 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|